⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Biogen added one new risk disclosure in 2025 focused on AI-based software risks to business and reputation, while substantively modifying four existing risks including those related to manufacturing facility investments, social media exposure, and capital market access. The company retained 25 unchanged risk factors, indicating that the majority of previously disclosed risk categories remained stable year-over-year. Overall, the risk factor section reflected evolving concerns around emerging technologies and operational challenges rather than fundamental shifts in Biogen's risk profile.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🟢 New in Current Filing The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation. 🔒

🟡 Modified We built a large-scale biologics manufacturing facility and are building a gene therapy, clinical packaging and other manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped. 🔒

🟡 Modified The increasing use of social media platforms presents new risks and challenges. 🔒

🟡 Modified We may not be able to access the capital and credit markets on favorable terms, which could increase our financing costs. 🔒

🟡 Modified Our business involves environmental and operational risks, which include the cost of compliance and the risk of contamination or injury. 🔒

5 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →